Literature DB >> 1510388

Susceptibility of Pseudomonas species to the novel antibiotics mureidomycins.

F Isono1, K Kodama, M Inukai.   

Abstract

Strains of Pseudomonas aeruginosa, including imipenem- or ofloxacin-resistant clinical isolates, and some other species in the genus Pseudomonas were inhibited by novel antibiotics of the mureidomycin (MRD) group. On the other hand, almost all other gram-positive and gram-negative bacteria were resistant to MRDs, though the antibiotics potently inhibited the in vitro peptidoglycan synthesis of Escherichia coli and P. aeruginosa. All of the strains in the genus Pseudomonas that were inhibited by less than or equal to 200 micrograms of MRDs per ml were classified into the rRNA groups I and III, and none of the tested strains of rRNA group I were resistant to MRDs, suggesting that these two groups are closely related to each other evolutionary. Among group I strains, P. aeruginosa, P. mendocina, P. stutzeri, and P. alcaligenes were more susceptible than the others, suggesting a closer relationship among these species.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510388      PMCID: PMC188829          DOI: 10.1128/AAC.36.5.1024

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Outer membrane barrier as a mechanism of antimicrobial resistance.

Authors:  H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

2.  DNA synthesis in nucleotide-permeable Escherichia coli cells. I. Preparation and properties of ether-treated cells.

Authors:  H P Vosberg; H Hoffmann-Berling
Journal:  J Mol Biol       Date:  1971-06-28       Impact factor: 5.469

3.  Emergence of resistance to imipenem in Pseudomonas aeruginosa.

Authors:  M J Lynch; G L Drusano; H L Mobley
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Use of intravenous ciprofloxacin in difficult-to-treat infections.

Authors:  H Giamarellou; N Galanakis
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis.

Authors:  F Isono; M Inukai
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. II. Structural elucidation.

Authors:  F Isono; M Inukai; S Takahashi; T Haneishi; T Kinoshita; H Kuwano
Journal:  J Antibiot (Tokyo)       Date:  1989-05       Impact factor: 2.649

7.  Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. I. Taxonomy, fermentation, isolation and physico-chemical properties.

Authors:  M Inukai; F Isono; S Takahashi; R Enokita; Y Sakaida; T Haneishi
Journal:  J Antibiot (Tokyo)       Date:  1989-05       Impact factor: 2.649

8.  Mureidomycins A-D, novel peptidylnucleoside antibiotics with spheroplast forming activity. III. Biological properties.

Authors:  F Isono; T Katayama; M Inukai; T Haneishi
Journal:  J Antibiot (Tokyo)       Date:  1989-05       Impact factor: 2.649

  8 in total
  4 in total

Review 1.  Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.

Authors:  Ellene H Mashalidis; Seok-Yong Lee
Journal:  J Mol Biol       Date:  2020-03-19       Impact factor: 5.469

2.  Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins.

Authors:  M Inukai; F Isono; A Takatsuki
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 3.  Identification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics.

Authors:  M McErlean; X Liu; Z Cui; B Gust; S G Van Lanen
Journal:  Nat Prod Rep       Date:  2021-07-21       Impact factor: 15.111

4.  Chemical logic of MraY inhibition by antibacterial nucleoside natural products.

Authors:  Ellene H Mashalidis; Benjamin Kaeser; Yuma Terasawa; Akira Katsuyama; Do-Yeon Kwon; Kiyoun Lee; Jiyong Hong; Satoshi Ichikawa; Seok-Yong Lee
Journal:  Nat Commun       Date:  2019-07-02       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.